Infinity Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals

INFI 0.0160

-4.8%

Sep 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (49)	7/25/2006 1:55:44 PM
From: Mike McFarland	of 210

Risk section, page 40 of the s-4a (toward the bottom) --by the way, for those folks like me who do not subscribe to edgar, if you access the filings through dpi's website you can get pdf or word files. Much easier to read and search: phx.corporate-ir.net Patents and patent applications owned or licensed by Infinity may become the subject of interference proceedings in the U.S. Patent Office to determine priority of invention. For example, Infinity is aware of third parties who are actively researching ansamycin analogs that are similar to Infinity’s lead candidate, IPI-504. These third parties have pending applications related to these analogs, but Infinity has the first published application covering IPI-504. It is possible that an interference could be declared between Infinity’s application covering IPI-504 and one or more of these third-party applications. An adverse decision in an interference proceeding may result in the loss of rights under a patent or patent application. In addition, the cost of interference proceedings to uphold the validity of patents can be substantial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next